Sen. Rick Scott Announces CLEAR LABELS Act to Hold Drug Manufacturers Accountable and Strengthen Supply Chain Oversight

Sen. Rick Scott Announces CLEAR LABELS Act to Hold Drug Manufacturers Accountable and Strengthen Supply Chain Oversight
January 29, 2026
WASHINGTON, D.C.
– Today, Senator Rick Scott announced the
Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act
to add country of origin labeling requirements to the U.S.’s prescription drug supply chain. Many prescription drugs, and their active pharmaceutical ingredients (APIs), are manufactured overseas, particularly in Communist China and India, and current federal labeling requirements do not require public disclosure of where those ingredients or finished products are made. As a result, patients, pharmacists, and health care providers often lack visibility into where their medicines are made. The
CLEAR LABELS Act
would require prescription drug labeling to disclose the original manufacturers of generic drugs and APIs, giving patients, providers, and regulators clear, upfront information about a drug’s origins.
This legislation builds on bipartisan efforts led by Senator Scott as chairman of the U.S. Senate Special Committee on Aging, including an
investigative report
and more than a
dozen inquiries
to federal agencies and industry leaders requesting information on the U.S.’s dangerous overreliance on foreign-manufactured generic drugs.
Senator Rick Scott
said, “Families want to feel safe; they want to know the drugs they take are safe, and they want to support American companies and American jobs. It is alarming just how many medicines Americans depend on are made overseas, in places like Communist China and India with limited transparency and oversight, leaving patients blindsided about where their drugs come from and unknowingly putting themselves at increased risk of death. My
CLEAR LABELS Act
takes a commonsense approach to fix that by requiring clear disclosure of the original manufacturers of these drugs and their components, known as APIs. Transparency is critical to protecting patient safety, strengthening oversight, and reducing America’s overreliance on foreign drug production. Americans deserve to have confidence that the medicines they take are safe, regulated, and clearly labeled.”
###
https://www.rickscott.senate.gov/2026/1/sen-rick-scott-introduces-clear-labels-act-to-hold-drug-manufacturers-accountable-and-strengthen-supply-chain-oversight